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eversal of Inappropriate Peripheral
ascular Responses in Hypertrophic Cardiomyopathy
ajesh Thaman, MD, MRCP,*† Perry M. Elliott, MD, MRCP, FACC,*† Jaymin S. Shah, MD, MRCP,*†
ryan Mist, PHD,*† Lynne Williams, MRCP,‡ Ross T. Murphy, MD, MRCP,*†
illiam J. McKenna, MD, FRCP, FACC,*† Michael P. Frenneaux, MD, FRCP, FACC‡
ondon and Birmingham, United Kingdom
OBJECTIVES We assessed the frequency of abnormal forearm vasodilator responses during lower body
negative pressure (LBNP) in 21 non-obstructive hypertrophic cardiomyopathy (HCM)
patients (31  8 [20 to 43] years) with abnormal blood pressure response (ABPR) to exercise
and the effects of three drugs used to treat vasovagal syncope (propranolol, clonidine, and
paroxetine) in a double-blind crossover study.
BACKGROUND Some HCM patients have an ABPR to exercise, which may be due to paradoxical peripheral
vasodilatation. A similar proportion has paradoxical forearm vasodilatation during central
volume unloading using LBNP. These abnormal reflexes may be caused by left ventricular
mechanoreceptor activation. Similar mechanisms may also contribute to some cases of
vasovagal syncope.
METHODS Blood pressure changes were assessed during exercise, and forearm vascular responses and
baroreceptor sensitivity were assessed during LBNP using plethysmography.
RESULTS Nine (43%) patients (group A) had paradoxical vasodilator responses (forearm vascular
resistance [FVR] fell by 7.5  4.6 U), and 12 (57%) patients (group B) had normal
vasoconstrictor responses during LBNP (FVR increased by 7.7  4.9 U). Paroxetine
augmented systolic blood pressure (SBP) during exercise in group A (21  6 mm Hg vs. 14 
11 mm Hg at baseline, p  0.02); no effect was detected in group B. Paroxetine reversed
paradoxical vascular responses during LBNP in seven (78%) patients from group A.
Propranolol and clonidine had no significant effect on SBP during exercise but reversed
paradoxical vascular responses in some patients from group A (n  5 and n  3).
CONCLUSIONS Paradoxical vasodilatation during LBNP occurs in 40% of patients with ABPR during
exercise and is reversed by propranolol, clonidine, and paroxetine. Paroxetine also improved
SBP response to exercise. (J Am Coll Cardiol 2005;46:883–92) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.053College of Cardiology Foundation
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pypertrophic cardiomyopathy (HCM) is an inherited heart
uscle disease characterized by unexplained left ventricular
LV) hypertrophy (1). Approximately one-third of patients
ith HCM exhibit an abnormal blood pressure response
ABPR) during erect exercise (either a blunted increase in
ystolic blood pressure [SBP] or, less commonly, a fall in
lood pressure) (2–4). This is associated with an increased
isk of sudden cardiac death, particularly if other risk factors
re present (3–8); ABPR may therefore be a potential
herapeutic target for interventions aimed at reducing the
isk of sudden cardiac death. We reported that ABPR was
ot primarily due to an impaired cardiac output response in
he majority of patients, but was due to an exaggerated fall
n systemic vascular resistance (SVR) (2,3). In health, SVR
alls between two- to three-fold during maximal erect
readmill exercise, a balance between vasodilatation in ex-
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nd Frenneaux were supported by the British Heart Foundation, and Dr. Murphy was
upported by a scholarship from Trinity College, Dublin.s
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ccepted April 19, 2005.rcising vascular beds and vasoconstriction in non-
xercising vascular beds. In patients with ABPR, the overall
all in SVR was more marked, and there was paradoxical
asodilatation in non-exercising vascular beds. Furthermore,
pproximately one-third of patients with HCM manifest a
aradoxical forearm vasodilator response during central
lood volume unloading (achieved by applying lower body
egative pressure [LBNP]) (9,11–13). We have previously
roposed that the abnormal vascular responses during exer-
ise and during LBNP in patients with HCM might both
e due to activation of stretch-sensitive LV mechanorecep-
ors, perhaps due to abnormal local wall strains (9). These
eceptors relay to the brainstem via non-myelinated vagal
fferents, and their firing tends to reduce sympathetic
fferent and increase vagal efferent activity from the brain
tem (13,14–16).
Vasovagal syncope is a common syndrome characterized
y hypotension with or without bradycardia after certain
rovocations including orthostatic stress. In patients with
asovagal syncope, abnormal (vasodilator) responses to
BNP and exercise are also commonly observed. Rarely
atients with vasovagal syncope may also develop hypoten-
ion during exercise (17–20). It is proposed that activation
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Vascular Responses in Hypertrophic Cardiomyopathy September 6, 2005:883–92f LV mechanoreceptors (stretch receptors) may be one of
he underlying triggers (although not necessarily the sole
ne) for vasovagal syncope (17,18,21). Recent trials have
hown that pharmacological treatment with beta-blockers,
lonidine, or paroxetine may be effective in reducing syn-
ope frequency in patients with vasovagal syncope (22–28).
Based on the potential similarity of pathophysiological
echanisms between abnormal vascular control in vasovagal
yncope and in HCM, we hypothesized that the same
harmacological agents used to treat vasovagal syncope
beta-blockers, clonidine, paroxetine) might attenuate ABPR
nd correct abnormal vascular responses during application
f LBNP in patients with HCM. We undertook a placebo-
ontrolled double-blind rotational study of these agents on
CM patients with documented ABPR, examining the
ffects on exercise blood pressure response and on the
orearm vascular response to application of LBNP.
ETHODS
he final study population comprised 21 (age 31  8 years,
ange 20 to 43 years, 9 men, 12 women) consecutive HCM
atients seen at the St. Georges Hospital Cardiomyopathy
linic. These patients were entered into a double-blind
rossover study design protocol. All patients demonstrated
BPR during a standard erect cycle exercise test and met
he entry criteria. All fulfilled World Health Organization
riteria for HCM (1). Patients with hypertension, other
Abbreviations and Acronyms
ABPR  abnormal blood pressure response
BRS  baroreceptor sensitivity
FBF  forearm blood flow
FVR  forearm vascular resistance
HCM  hypertrophic cardiomyopathy
LBNP  lower body negative pressure
LV  left ventricle/ventricular
NBPR  normal blood pressure response
SBP  systolic blood pressure
SVR  systemic vascular resistance
VO2  oxygen consumption
%VO2max  percentage of the predicted maximal VO2
Table 1. Study Protocol
Medication Weeks Morning
Placebo 3 Placebo
Clonidine phase 1 Clonidine 50 g
2 Clonidine 100 
3 Clonidine 100 
Placebo 3 Placebo
Propranolol phase 1 Propranolol SR 1
2 Propranolol SR 3
3 Propranolol SR 3
Placebo 3 Placebo
Paroxetine phase 1 Paroxetine 20 m
2 Paroxetine 40 m
3 Paroxetine 40 mPlacebo 3 Placeboardiac or systemic diseases that could produce hypertrophy,
rimary valvular heart disease, atrial fibrillation, history of
epatic or renal disease, significant LV outflow tract gradi-
nt (30 mm Hg), or contraindications to drug therapy
sed in this study were excluded. All patients with signifi-
ant chest pain or exertional dyspnea underwent coronary
rteriography, and four patients who were found to have
bstructive coronary artery disease defined as 50% stenosis
n one or more coronary arteries were excluded. All cardio-
ctive medications were withdrawn for at least five half-lives
efore evaluation and for the duration of the study.
Initial clinical evaluation included history, examination,
2-lead electrocardiogram, two-dimensional and M-mode
chocardiography, 48-h Holter, and symptom-limited car-
iopulmonary exercise testing on an erect cycle with mea-
urement of blood pressure response; ABPR was defined as
ither a failure of SBP to rise by at least 25 mm Hg or a fall
n SBP from the peak value during exercise of at least 10
m Hg (7,29).
tudy protocol. After baseline evaluation, patients entered
rotational drug study during which they were given in
andom order: propanolol, paroxetine, clonidine, or placebo
or three weeks, each with a washout period of three weeks
n between each phase during which time patients received
lacebo. All trial medication and placebo were placed in
apsules, and one capsule was taken three times a day (Table
). Both investigator and patient were blinded to the type of
herapy.
At the end of each three-week period, the effect of
reatment was assessed by cardiopulmonary exercise testing
ith measurement of blood pressure response. Forearm
ascular resistance (FVR), forearm blood flow (FBF), and
aroreceptor sensitivity (BRS) were assessed before and
uring application of LBNP.
The study protocol was approved by the hospital local
esearch ethics committee, and all patients gave written
nformed consent before participating.
ardiopulmonary exercise testing. All 21 patients under-
ent maximal cardiopulmonary exercise testing on a bicycle
rgometer (Sensormedics Ergometrics 800S) using an in-
remental ramp protocol of 10 to 15 W/min with respira-
Afternoon Evening
Placebo Placebo
Clonidine 50 g Clonidine 50 g
Clonidine 100 g Clonidine 100 g
Clonidine 100 g Clonidine 100 g
Placebo Placebo
g Placebo Placebo
g Placebo Placebo
g Placebo Placebo
Placebo Placebo
Placebo Placebo
Placebo Placebo
Placebo Placebog
g
60 m
20 m
20 m
g
g
gPlacebo Placebo
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September 6, 2005:883–92 Vascular Responses in Hypertrophic Cardiomyopathyory gas sampling (V Max 29 Console, Sensormedics),
2-lead electrocardiogram, and measurement of blood pres-
ure during exercise. Patients cycled at a rate of 60 to 70
evolutions per min to the point of symptom limitation;
lood pressure was recorded at 2-min intervals during
xercise and for 10 min into recovery by a cuff sphygmo-
anometer. Peak oxygen consumption (peak VO2) was
efined as the highest VO2 achieved during exercise. Results
ere expressed as a percentage of the predicted maximal
O2 (%VO2max) to allow for age, gender, and body size.
ssessment of forearm vascular responses during appli-
ation of LBNP. Patients were studied in a quiet environ-
ent at a constant room temperature of between 22°C and
4°C. Patients were asked to lie supine in a specially
onstructed lower body suction bed encased from below the
liac crests in an airtight seal. A small transducer measured
he pressure within the device. Heart rate and blood
ressure changes were recorded using the Finapres (Ohm-
da 2300, Anglewood) apparatus. This consists of a front-
nd box worn on the wrist with two finger cuffs and a waist
elt. The cuffs were placed on the ring and middle fingers
nd inflated alternately in order to avoid prolonged cuff
nflation in a single finger. The waist belt houses a battery
nd microcomputer, which stores beat-to-beat pressure data
ncluding systolic, diastolic, and mean arterial pressures and
ulse rate. The software identifies height of systolic up-
troke, time of upstroke, mean arterial pressure, and arterial
nd-diastolic pressure for each heart beat. Data from the
inapress were used to calculate BRS using the validated
equence analysis of beat-to-beat interaction of SBP with
-R interval as described by Blaber et al. (30). Baroreceptor
ensitivity was calculated before application of LBNP and 2
in after commencing application of LBNP.
Forearm blood flow was assessed before and during
pplication of 20 mm Hg LBNP using mercury in silastic
train gauge plethysmography (Hokanson). A strain gauge
as placed around the left forearm approximately 5 cm
elow the antecubital crease. A cuff was placed around the
pper forearm. Circulation to the hand was occluded by
nflating another small cuff placed around the wrist to
uprasystolic pressures. Measurements of FBF were ob-
ained by inflating the forearm cuff to 40 mm Hg to prevent
enous return. The rate of increase of forearm girth is then
roportional to FBF. The cuff was inflated to 40 mm Hg for
0 s and deflated for 10 s. This was repeated three times,
nd the forearm flow was calculated from the mean of three
lopes. Forearm vascular resistance was calculated as the
uotient of the mean arterial pressure (mm Hg) and FBF
ml/min/per 100 ml) and expressed in resistance units.
atients were divided into those in whom FVR fell during
BNP (group A) versus those in whom it increased (group
). According to the prespecified study design, analysis of
he effects of therapy was performed separately in these two
roups of patients. All physiological variables recorded were
cquired and stored using Powerlab, Chart for Windows
e
poftware, on a Dell Inspiron 5000e computer and measure-
ents were analyzed off-line.
tatistics. Statistical analysis was performed using SPSS
version 10.0) statistical software (SPSS Inc., Chicago,
llinois). All data are presented as mean  SD unless
therwise stated. A paired sample t test was used to assess
reatment effects for each individual treatment arm, as a
ifference from baseline values (31). The chi-square test was
sed to compare frequencies of dichotomous variables.
nalysis of covariance (ANCOVA) was used to examine
he influence of baseline changes in FVR and FBF on drug
ffect. All analyses were performed on a per-protocol basis.
p value of 0.05 was regarded as significant.
ESULTS
aseline data. The baseline demographic, clinical, and
chocardiographic characteristics of the 21 patients studied
re summarized in Table 2. No patients had a history of
able 2. Baseline Characteristics of Patients Studied
otal number of patients 21
ge (yrs) 31  8 (20 to 43)
ge at diagnosis (yrs) 23  6 (16 to 33)
YHA functional class
1 3 (14%)
2 17 (81%)
3 1 (5%)
hest pain 8 (38%)
yncope/presyncope 9 (43%)
SVT 3 (14.3%)
LVWT (mm) 20  5 (15 to 35)
SH 18 (86%)
oncentric 1 (5%)
pical 2 (10%)
VEDD (mm) 41  3 (34 to 47)
VESD (mm) 23  3 (18 to 26)
A (mm) 40  8 (32 to 62)
S (%) 43  5 (35 to 51)
VOTG (mm Hg) 8  7 (0 to 24)
/A 2.2  0.9 (1.1 to 3.0)
T (ms) 200  34 (151 to 244)
VRT (ms) 100  5 (95 to 133)
xercise time (min) 8.03  1.45 (6.01 to 12.32)
ER (l/min) 1.1  0.1 (1.0 to 1.2)
VO2 max 78  19 (47 to 109)
2 pulse (ml/beat) 11.0  2.7 (5.6 to 16.0)
R rest (beats/min) 75  16 (51 to 120)
R peak exercise (beats/min) 155  21 (111 to 184)
PHR 85  10 (61 to 99)
BP rest (mm Hg) 109  9 (90 to 130)
BP peak exercise (mm Hg) 127  13 (110 to 150)
hange in SBP (mm Hg) 17  8 (10 to 25)
alues are n (%), or mean  SD (95% confidence interval).
ASH  asymetric septal hypertrophy; DT  deceleration time; FS  fractional
hortening; HR  heart rate; IVRT  interventricular relaxation time; LA  left
trium diameter; LVEDD  left ventricular end-diastole diameter; LVESD  left
entricular end-systole diameter; LVOTG  left ventricular outflow tract gradient;
LVWT  maximal left ventricular wall thickness; NSVT  nonsustained ventric-
lar tachycardia; NYHA  New York Heart Association; O2 pulse  oxygen pulse
VO2 [ml]/heart rate [beats/min]); PHR  % of predicted heart rate achieved during
xercise; RER  respiratory reserve ratio; SBP  systolic blood pressure; VO2 max 
ercentage of the predicted maximal oxygen consumption during exercise.
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Vascular Responses in Hypertrophic Cardiomyopathy September 6, 2005:883–92revious cardiac arrest or ventricular fibrillation. Three
atients had an implantable cardioverter-defibrillator for
revention of sudden cardiac death, but no discharges had
een recorded. Eight of the patients entered into the study
ad undergone coronary angiography and were found to
ave no significant epicardial coronary artery stenosis.
All patients performed an adequate exercise test (respira-
ory exchange ratio 1.0), the mean exercise duration being
.03 1.45 min. Exercise was terminated because of fatigue
n 67%, breathlessness in 29%, and chest discomfort in 5%.
he mean %VO2max achieved was 78% 19%. A reduction
n SBP of 10 mm Hg from baseline at the start of exercise
as seen in 5% of patients, and the other 95% had a flat
lood pressure response (i.e., 25 mm Hg increase). No
atients became syncopal or had a significant arrhythmia
uring exercise.
VR during application of LBNP. Nine patients (43%)
ad an abnormal vasodilator response to LBNP (group A).
n these patients, FVR fell by 7.5  4.6 U associated with
n increase in FBF of 0.56  0.37 ml/min1. The remain-
ng 12 patients (57%) had a normal vasoconstrictor response
o LBNP (group B). In these patients FVR increased by
Table 3. Clinical Characteristics of Patients in
Group A
Number of patients 9 (43%)
Age (yrs) 32.7  8.3 (22 to
NYHA functional class
1 1
2 8
3 0
Chest pain 5 (55.5%
Syncope/presyncope 6 (66.7%
NSVT 2
ICD 2
MLVWT (mm) 21  4 (16 to 3
ASH 9
Concentric 0
Apical 0
LVED (mm) 40.7  3.6 (34 to
LVES (mm) 21.7  3.4 (18 to
FS (%) 46.6  6.9 (37 to
LA (mm) 38.7  5.3 (34 to
LVOTG (mm Hg) 10  7 (4 to 24
E/A 1.9  0.6 (1.5 t
DT (ms) 209  41 (175 to
IVRT (ms) 103  9 (95 to 1
Exercise time (min) 8.13  1.12
RER (l/min) 1.08  0.06 (0.98
%VO2 max 82  19 (49 to
O2 pulse (ml/beat) 11.7  2.2 (9.4 to
Resting HR (beats/min) 77  22 (58 to
Peak HR (beats/min) 156.7  19.8 (128
%PHR 85.0  7.8
Resting SBP (mm Hg) 106  9 (90 to 1
Increment in SBP during
exercise (mm Hg)
14  11 (10
Resting FVR (U) 47.2  12.6 (35 t
Resting FBF (ml/kg/min1) 3.12  1.0 (1.1 toFBF  forearm blood flow; FVR  forearm vascular resist
abbreviations as in Table 2..7  4.9 U associated by a fall in FBF of 0.8  0.6
l/min1.
aseline characteristics of patients from groups A and
. Table 3 shows the baseline clinical characteristics of
atients in groups A and B. Patients in group A had a
igher prevalence of syncope (66% vs. 25%), a smaller LV
nd-systole diameter (21.7 mm vs. 27.4 mm), and greater
ercentage of fractional shortening (46.6% vs. 39.7%) than
atients in group B. There were no other significant
ifferences in clinical or echocardiographic characteristics,
ncluding severity of outflow tract obstruction. Resting FVR
nd FBF, resting SBP, and the increment in SBP during
xercise were similar in the two groups.
he effect of medications. The effect of medications on
xercise variables and forearm vascular reflexes during ap-
lication of LBNP are shown in Tables 4 and 5 and Figures
and 2, respectively. There were no carryover effects noted
t the end of each washout period.
LACEBO. Compared to baseline, placebo therapy was not
ssociated with any significant changes in exercise duration,
ercentage of VO2, resting SBP, or in the increment in SBP
ups A and B
Group B p Value
12 (57%) —
29.8  8.4 (20 to 41) 0.56
2
9
1 0.51
3 (25%)
3 (25%) 0.03
1 —
1 —
18  5 (15 to 25) 0.63
9 —
1 —
2 —
45.1  7.2 (35 to 47) 0.09
27.4  6.2 (19 to 25) 0.02
39.7  6.8 (35 to 51) 0.04
41.4  8.9 (32 to 62) 0.06
6  5 (0 to 7) 0.07
1.6  0.7 (1.1 to 2.0) 0.06
190  55 (151 to 230) 0.75
109  3 (100 to 125) 0.81
9.10  0.32 0.85
.14) 1.09  0.07 (1.04 to 1.21) 0.65
77  21 (47 to 103) 0.32
) 10.7  3.1 (5.6 to 13.5) 0.37
69.5  11.4 (51 to 86) 0.47
1) 149.7  27.1 (111 to 184) 0.62
85.1  12.9 0.25
111  10 (100 to 130) 0.11
19  4 (10 to 25) 0.08
41  12.9 (14 to 61) 0.14
3.6  0.8 (2.4 to 5.0) 0.12Gro
43)
)
)
5)
44)
26)
47)
49)
)
o 3)
244)
15)
to 1
109)
16.0
120)
to 18
20)
to 25)
o 73)
4.2)
Values are n (%), or mean  SD (95% confidence interval).
ance; ICD  implantable cardioverter defibrillator; other
Table 4. Effect of Medication on Exercise Indexes in the Whole Population (n  21)
Baseline Propranolol p Clonidine p Paroxetine p Placebo p
Exercise time (mins) 8.0  1.4 (6.0 to 12.3) 7.6  1.9 (5.4 to 11.2) 0.31 7.3  1.6 (5.3 to 10.4) 0.12 7.6  16 (5.6 to 11.0) 0.21 7.8  1.0 (5.3 to 12.0) 0.66
%VO2 max 78  19 (47 to 109) 70  17 (43 to 94) 0.16 74  16 (40 to 93) 0.32 72  16 (46 to 94) 0.34 76  17 (45 to 103) 0.31
O2 pulse 11.0  2.7 (5.6 to 16.0) 12.1  2.9 (6.5 to 16.9) 0.14 12.1  2.7 (9.1 to 16.0) 0.17 11.7  2.1 (9.2 to 15.7) 11.0  2.3 (5.5 to 15.6) 0.38
HR rest 75  16 (51 to 120) 60  7 (50 to 72) 0.03 69.0  13 (57 to 81) 0.35 71  11 (63 to 96) 0.71 79  11 (53 to 107) 0.45
HR peak 155  21 (111 to 184) 130  22 (80 to 160) 0.02 148  18 (92 to 173) 0.40 146  30 (89 to 187) 0.62 148  20 (119 to 182) 0.40
% PHR 83  11 (61 to 95) 68  10 (44 to 83) 0.01 79.0  12 (52 to 92) 0.28 78  16 (50 to 97) 0.42 85  10 (60 to 97) 0.61
RER 1.1  0.1 (1.0 to 1.2) 1.06  0.04 (0.95 to 1.1) 0.21 1.07  0.05 (0.95 to 1.12) 0.46 1.09  0.14 (0.5 to 1.14) 0.80 1.09  0.1 (1.0 to 1.2) 0.37
SBP rest 109  9 (90 to 120) 103  9 (90 to 120) 0.04 100  9 (85 to 120) 0.32 104  12 (80 to 120) 0.40 100  10 (85 to 130) 0.51
SBP peak 127  13 (110 to 150) 120  10 (110 to 140) 0.05 124.4  10.1 (110 to 135) 1.01 131  13.5 (105 to 150) 0.21 130  13 (110 to 150) 0.75
SBP change 17  8 (10 to 25) 16  6 (5 to 25) 0.90 16.8  5.3 (10 to 25) 0.40 26.5  7.5 (15 to 40) 0.02 18  8 (5 to 25) 0.81
Values are mean SD (95% confidence interval). p values relate to the comparison between variables at baseline and after 3 weeks of medication. In the case of clonidine however comparisons are made only in those patients who completed
treatment rather than on an intention-to-treat basis.
Abbreviations as in Table 2.
Table 5. Effect of Medication on Forearm Vascular Reflexes
Group A Baseline Propranolol p Clonidine p Paroxetine p Placebo p
FBFrest 3.12  1.0 (1.1 to 4.2) 2.6  0.9 (0.9 to 3.9) 0.29 3.1  0.4 (2.7 to 3.8) 0.35 2.8  1.0 (1.1 to 4.0) 0.55 3.06  1.0 (1.0 to 4.12.4, 4.0) 0.35
FVRrest 47.2  12.6 (35 to 73) 53.0  15.0 (36 to 81) 0.42 42.8  7.7 (35 to 51) 0.70 50.5  15.8 (32 to 77) 0.63 48.0  12.0 (36 to 79) 0.45
FBFLBNP 3.7  1.0 (1.6 to 5.1) 2.5  1.0 (0.7 to 4.1) 0.001 3.1  0.4 (2.6 to 3.6) 0.02 2.6  1.2 (0.6 to 3.9) 0.04 3.4  1.0 (1.2 to 4.7) 0.61
FVRLBNP 39.7  13.7 (24 to 62) 58.3  30.3 (31 to 129) 0.05 46.0  13.4 (34 to 62) 0.05 58.1  37.7 (29 to 119) 0.07 40.7  11.7 (26 to 57) 0.32
FBFchange 0.7  0.4 (0.1 to 1.2) 0.1  0.3 (0.5 to 0.3) 0.001 0.04  0.3 (0.3 to 0.3) 0.01 0.2  0.4 (0.7 to 0.4) 0.01 0.5  0.4 (0.1 to 1.0) 0.76
FVRchange 7.6  4.6 (16 to 1) 5.5  16.5 (5 to 48) 0.05 3.2  6.6 (4 to 11) 0.001 7.5  13.6 (4 to 42) 0.0017.1  4.4 (14 to 1.2) 0.34
Group B
FBFrest 3.6  0.8 (2.4 to 5.0) 2.6  0.7 (1.4 to 3.9) 0.005 2.9  0.7 (1.9 to 4.0) 0.02 3.14  0.7 (2.1 to 4.4) 0.16 3.3  0.8 (2.1 to 5.0) 0.52
FVRrest 41  12.9 (14.1 to 61.0) 49.8  9.8 (32 to 66) 0.08 49.2  12.5 (29 to 69) 0.01 49.3  13.4 (21 to 64) 0.13 38  14.5 (9.0 to 57.3) 0.70
FBFLBNP 2.8  0.6 (1.5 to 3.8) 1.8  0.7 (1 to 3) 0.001 2.3  0.9 (1.2 to 3.9) 0.06 2.35  0.5 (1.7 to 3.1) 0.06 2.7  0.6 (1.5 to 3.7) 0.46
FVRLBNP 48.7  11.1 (31 to 63) 55.7  11.7 (38 to 76) 0.16 53.1  13.9 (36 to 82) 0.27 54.9  14.2 (28 to 71) 0.25 46.9  11.0 (31 to 60) 0.50
FBFchange 0.8  0.6 (2.4 to 0.3) 0.7  0.3 (1.7 to 0.2) 0.19 0.6  0.7 (2.4 to 0.1) 0.65 3.7  10.4 (36.7 to 0.2) 0.65 0.6  0.5 (2.1 to 0.2) 0.34
Values are mean  SD (95% confidence interval). p values relate to the comparison between variables at baseline and after three weeks of medication. In the case of clonidine, however, comparisons are made only in those patients who
completed treatment rather than on an intention-to-treat basis.
LBNP  20 mm Hg lower body negative pressure; other abbreviations as in Table 3.
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Vascular Responses in Hypertrophic Cardiomyopathy September 6, 2005:883–92uring exercise. No patient with an ABPR developed a
ormal blood pressure response (NBPR) to exercise. There
as no significant change in the forearm vascular response
o application of LBNP in patients in either group A or B,
nd no patients from group A changed from a vasodilator to
vasoconstrictor response to LBNP.
ROPANOLOL. All patients achieved target doses without
dverse effects. After three weeks of propanolol therapy,
our (44%) patients from group A and three (25%) from
roup B reported less chest pain and reduced breathlessness
s shown in Table 4. Propanolol was associated with a
ignificant reduction in resting heart rate, peak exercise
eart rate, percentage of predicted heart rate achieved
uring exercise, and resting SBP; %VO2max was not signif-
cantly different from baseline, and there was no significant
hange in the increment in SBP during exercise in the entire
roup, or for group A or B separately (Table 4); however,
ne patient from group A converted to an NBPR during
xercise on propanolol.
Propanolol therapy was associated with significant
hanges in FVR and FBF during application of LBNP in
roup A patients: mean FVR increased by 5.5 (95% confi-
ence interval [CI] 7.2 to 18.3) on propranolol compared
o a mean reduction of 7.6 (95% CI 4.0 to 11.0) at
aseline (p  0.05), and FBF decreased by 0.1 (95% CI
0.3 to 0.2) on propranolol compared with an increase of
.7 (95% CI 0.3 to 0.9) at baseline (p  0.001). This effect
as independent of baseline changes in FVR on propranolol
igure 1. Change in forearm vascular resistance (FVR) before and during l
hisker plot for the change in FVR during LBNP in each treatment arm.
median  interquartile range  6  15, 5  9, 3  53, 4  15, 6 
hiskers represent the maximum and minimum values for each treatmens assessed by ANCOVA. Paradoxical vascular responses to cBNP normalized in five (71%) patients in group A and
emained vasodilator in the remaining four (29%) patients.
orearm vascular responses remained vasoconstrictor after
ropanolol in all patients from group B. The results are
ummarized in Table 5.
LONIDINE. Clonidine was poorly tolerated by 11 (52%)
atients and was discontinued by 9 (43%) patients (4
atients from group A and 5 from group B) due to severe
ethargy, dizziness, or nausea. In patients who were able to
olerate clonidine, an improvement in symptoms (reduced
reathlessness) was reported by one patient from group A
nly. Only 12 patients completed the clonidine phase of the
tudy and underwent repeat studies. Because this study was
esigned to assess the effect of these drugs on pathophysi-
logical mechanisms, we present the data for the remainder
ho had paired data, rather than analyzing on intention-
o-treat principles. As shown in Table 4, on cardiopulmo-
ary exercise testing compared to baseline, there were no
ignificant changes in resting heart rate, peak heart rate,
ercent of predicted heart rate achieved during exercise,
VO2max, or resting SBP. There was no significant differ-
nce in the increment in SBP during exercise for the entire
roup, or for group A or B separately. No patient with an
BPR developed an NBPR on clonidine.
As shown in Table 5, compared to baseline, clonidine was
ssociated with significant changes in FVR and FBF during
pplication of LBNP in patients from group A: mean FVR
ncreased by 3.2 (95% CI 5.0 to 11.4) on clonidine
body negative pressure (LBNP) at baseline and after medication. Box and
oxes represent the median and interquartile range for each treatment arm
or baseline, placebo, propranolol, clonidine, and paroxetine, respectively).
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September 6, 2005:883–92 Vascular Responses in Hypertrophic Cardiomyopathyo 11.0) at baseline (p  0.001), and FBF decreased by
0.04 (95% CI 0.3 to0.3) on clonidine compared with an
ncrease of 0.7 (95% CI 0.3 to 0.9) at baseline (p  0.01).
his effect was independent of baseline changes in FVR on
lonidine as assessed by ANCOVA. Paradoxical vascular
esponses normalized in three (60%) patients in group A
nd remained vasodilator in two (40%). Forearm vascular
esponses remained vasoconstrictor in all patients from
roup B (Table 5).
AROXETINE. In four (44%) patients from group A and two
17%) from group B, presyncope and lethargy were reported
uring the first week of paroxetine, although this did not
equire discontinuation of therapy. Side effects resolved by
he third week of therapy in all patients. Less chest pain and
reathlessness were reported by the end of week three in
3% of patients in group A and 8% of group B. As shown
n Table 4, on cardiopulmonary exercise testing compared to
aseline, there were no significant changes in resting heart
ate, peak exercise heart rate, percentage of predicted heart
ate achieved during exercise, %VO2max, or resting SBP.
here was a significant augmentation in the SBP response
o exercise on paroxetine compared to baseline in group A
atients (21  6, 95% CI 16.2 to 27.1 vs. 14  11, 95% CI
.0 to 21.8 mm Hg increment in SBP, p  0.02), and five
55%) patients from group A were reclassified as having an
BPR on paroxetine. In these patients, SBP increased by
5  3 mm Hg compared to 15  3 mm Hg at baseline
p 0.001). In patients from group B, no significant change
n SBP response to exercise was recorded compared to
aseline, and no patient developed an NBPR.
Paroxetine therapy was also associated with significant
hanges in FVR and FBF during application of LBNP in
igure 2. Change in forearm vascular resistance (FVR) before and during l
hisker plot for the change in FVR during LBNP in each treatment arm.
median  interquartile range  7.0  15.0, 5.5  10.0, 6.0  25.0, 5.0 
espectively). Whiskers represent the maximum and minimum values forroup A patients: mean FVR increased by 7.6 (95% CI a2.9 to 18.1) on paroxetine compared to a mean reduction
f7.6 (95% CI4.0 to11.0) at baseline (p 0.01), and
BF decreased by 0.2 (95% CI 0.5 to 0.05) on parox-
tine compared with an increase of 0.7 (95% CI 0.3 to 0.9)
t baseline (p  0.001). This effect was independent of
aseline changes in FVR on paroxetine as assessed by
NCOVA. Paradoxical vascular responses normalized in
even (78%) of patients in group A. Forearm vascular
esponses remained vasoconstrictor in all patients from
roup B (Table 5).
RS. At initial evaluation, BRS was significantly lower in
atients from group A than group B before applying LBNP
5.73  0.48 vs. 8.29  2.01, p  0.01). During LBNP
here was a further reduction in BRS in patients from group
(by 5.73  6.76), whereas in group B there was a mean
ncrease in BRS (by 0.93  6.13). Medications had no
ignificant effect on BRS in patients from groups A or B
Table 6).
ISCUSSION
here are four important findings of this study. First,
pproximately 40% of patients with ABPR during erect
ycle exercise exhibited paradoxical forearm vasodilatation
uring application of LBNP. Second, both the exercise
lood pressure response and the forearm vascular response
uring application of LBNP are reproducible as shown by
he placebo limb of the study. Third, exercise blood pressure
esponses were improved by paroxetine therapy, and abnor-
al forearm vascular responses during application of LBNP
ere attenuated or normalized by propranolol, clonidine,
body negative pressure (LBNP) at baseline and after medication. Box and
oxes represent the median and interquartile range for each treatment arm
, 6.0  50.0 for baseline, placebo, propranolol, clonidine, and paroxetine,
treatment arm.ower
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naffected by any of these therapies.
echanism of abnormal vascular responses in HCM. In
an, the forearm vasoconstriction response to application of
ubhypotensive LBNP appears to be predominantly medi-
ted by inactivation of LV mechanoreceptors. The paradox-
cal forearm vasodilatation in some HCM patients most
ikely represents abnormal activation of LV mechanorecep-
ors (9,11). We have previously suggested that ABPR
uring exercise may also be due to abnormal activation of
V mechanoreceptors (7). The reason for this is unknown,
ut possible causes include intrinsic abnormalities of ven-
ricular mechanoreceptors or increased LV local wall strains,
ue either to high intraventricular pressures or to the
yocyte disarray and fibrosis, which characterizes the dis-
rder. Whatever the mechanism, excessive or inappropriate
fferent input from ventricular mechanoreceptors during
xercise could overcome the normal constrictor input from
entral command and skeletal muscle afferents resulting in a
ithdrawal of sympathetic efferent outflow from the brain-
tem and consequently inappropriate peripheral vasodilata-
ion and hypotension. However, this is speculative, and
here is as yet no direct proof that these abnormal vascular
esponses are triggered by LV mechanoreceptor activation.
echanism of action of pharmacologic interventions. All
hree drugs studied normalized or attenuated the abnormal
orearm vasodilatation associated with application of
BNP; however, only paroxetine therapy was associated
ith an improvement in blood pressure response to exercise.
t should be noted that the effects of clonidine in this study
ere more difficult to ascertain due to the high withdrawal
ate, which might also be expected to limit any possible
herapeutic potential. It is also important to note that,
lthough no patient reported adverse effects on withdrawal
f any of the medications used in this study, all three may be
ssociated with rebound symptoms on sudden withdrawal,
nd therefore caution should be exercised before discontinu-
ng any of these medications, particularly when used over a
ong period of time.
The three drugs are thought to act at different points
long the baroreflex arc (32,33). Beta-blocking agents are
hought to act through their negatively inotropic actions,
pposing the stretch stimulation of the LV mechanorecep-
ors, although they have also been shown to have central
ctions that tend to reduce sympathetic efferent activity and
romote cardiac vagal outflow. Clonidine is an alpha-
drenoceptor agonist, the pathophysiological basis for the
ction of clonidine is based on its partial selective alpha 2
gonist activity. Clonidine acts peripherally on alpha 2
eceptors in large capacitance vessels significantly reducing
enous capcitance, thus decreasing the likelihood of trig-
ering the vasovagal reflex after gravitational stress (33).
lonidine also acts centrally on vasomotor areas within the
rain stem leading to a reduction in tonic sympathetic
fferent activity within the brain stem and noripherherine
elease (hence its use as an antihypertensive); clonidine may Ta
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September 6, 2005:883–92 Vascular Responses in Hypertrophic Cardiomyopathylso stimulate tonic parasympathetic outflow, and more
ecently it has been suggested that clonidine may act on
midazole receptors. Clonidine also appears to prevent acute
eductions in sympathetic efferent activity in vasovagal
yncope and in carotid sinus syndrome (34–37). Paroxetine
s a highly selective serotonin (5HT) re-uptake inhibitor
nd has been shown to provide functional improvement in
atients with vasovagal syncope (26–28). The mechanism
y which this occurs is unclear, but animal and human
vidence support a sudden increase in 5HT levels within the
rainstem with activation of 5HT-2 receptors as a key to the
echanism of vasovagal syncope. Paroxetine is thought to
ct by down-regulating 5HT receptors and thereby increas-
ng the threshold for the vasovagal response (37–42).
linical significance. Abnormal blood pressure response
uring exercise defines a subset of patients generally at
ncreased risk of sudden cardiac death (2–6). Although
nproven, it has been suggested that episodic hypotension
ay result in myocardial ischemia and that in patients with
n underlying electrical instability due to myocyte disarray
nd fibrosis, this may provide the trigger for ventricular
rrhythmia. The association in the present study between
bnormal forearm vascular responses during application of
BNP and a history of syncope suggests that abnormal
ascular responses might also be involved in the pathophys-
ology of syncope in some patients. By reversing or attenu-
ting the ABPR during exercise, and the abnormal vascular
esponse during abrupt reductions in central blood volume,
aroxetine may potentially reduce the number or severity of
ypotensive episodes and/or syncope in patients with HCM
nd ABPR, and might conceivably reduce the risk of sudden
ardiac death. Longitudinal placebo-controlled studies are
equired to verify or refute this hypothesis.
Despite the fact that 55% of patients with ABPR were
eclassified as having a “NBPR” after paroxetine therapy, the
ncrease in SBP during exercise in these patients was still
elatively modest (25 to 30 mm Hg). The definition of ABPR
mployed in this study (increase in SBP25 mm Hg) is based
n studies examining the impact on prognosis (7,29). Previous
ata from a series of untrained normal individuals of similar
ge and gender in our own department showed an average
ncrease in SBP of 58  18 mm Hg (40 to 90 mm Hg).
herefore, although there was an improvement in SBP after
aroxetine, the BPR response in these patients remains abnor-
al compared to unaffected individuals.
tudy limitations. The main limitation of this study is that
orearm vascular responses were not recorded during erect
xercise. This is because of the inherent limitations in
erforming plethysmogaphy during exercise due to move-
ent artefact. Therefore, we cannot exclude the possibility
hat the beneficial effect of paroxetine on exercise blood
ressure response was due to a higher cardiac output rather
han a normalization of the vascular response. However,
aroxetine has no known effects on cardiac performance,
nd in the present study had no effect on oxygen pulse
Table 4), which argues strongly against this. Secondly, nonvasive hemodynamic measurements were performed, so
e cannot be certain that central venous pressure decreased
qually during application of LBNP in patients with and
ithout vasodilatory forearm vascular responses. However,
n a previous study using the same methodology, we showed
hat the fall in central venous pressure was similar in the two
roups (9).
Finally, in this study we have inferred that ABPRs during
xercise and abnormal vascular responses during central
olume unloading using LBNP in patients with HCM are
robably linked mechanistically. Although little direct evi-
ence for this exists, studies have shown that both responses
ccur in a similar proportion of HCM patients, both are due
o peripheral vasodilatation in certain vascular beds includ-
ng forearm vasculature, and it is probable that both are
riggered by LV mechanoreceptor activation.
onclusions. Our data suggest that abnormal vascular
esponses in HCM may be favorably modified by pharma-
ological therapy. Propranolol, clonidine, and paroxetine
ere each effective in reversing or attenuating abnormal
orearm vasodilator responses during application of LBNP,
nd paroxetine also improved blood pressure response to
xercise.
eprint requests and correspondence: Dr. Rajesh Thaman, The
eart Hospital, Cardiology, 16-18 Westmoreland Street, London,
1G 8PH, United Kingdom. E-mail: rajesh.thaman@
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